---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-119791"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2024-11-01T23:59:59+00:00"
generated_at: "2026-05-30T06:53:19.252649+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q3 2024 revenue up 35% to $18.2M; lung diagnostic revenue grows 40% YoY

## Summary
- Total revenue $18.2M (+35% YoY); lung diagnostic revenue $17.2M (+40% YoY).
- Net loss improved 6% to $10.3M; Adjusted EBITDA loss $5.6M.
- Gross profit margin 77.0% vs 76.1% in Q3 2023; test volume 13,900 (+34% YoY).
- Reiterated FY 2024 revenue guidance $70M-$72M; targeting Adjusted EBITDA profitability H2 2025.
- Presented Nodify XL2/CDT data at CHEST; launched CLARIFY study for diverse patient data.

## SEC filing metadata
- accession: 0000950170-24-119791
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2024-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017024119791/0000950170-24-119791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017024119791/bdsx-20241101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-119791
- JSON: https://secwatch.observer/filing/0000950170-24-119791.json
- Plain text: https://secwatch.observer/filing/0000950170-24-119791.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.